STOCK TITAN
  1. Home
  2. Sec-filings
  3. COCP
  4. [8-K] Cocrystal Pharma, Inc. Reports Material Event

Cocrystal Pharma (NASDAQ: COCP) names Carol L. Brosgart to its board

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. (COCP) reported that its Board of Directors appointed Carol L. Brosgart as a director, effective August 12, 2026. The company states there are no arrangements or understandings with other persons regarding her selection, no family relationships with current directors or executive officers, and no related party transactions involving her that require disclosure under Item 404(a) of Regulation S-K.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Appointment effective date August 12, 2026 Effective date of Carol L. Brosgart’s appointment as director
Commission File Number 001-38418 SEC file number for Cocrystal Pharma, Inc.
CFO signature date August 18, 2026 Date James Martin signed the report as Chief Financial Officer
Corporate telephone number (877) 262-7123 Registrant’s telephone number listed for Cocrystal Pharma, Inc.
Principal office ZIP code 98011 ZIP code for 19805 N. Creek Parkway, Bothell, WA
Emerging growth company regulatory
"405) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 404(a) of Regulation S-K regulatory
"transactions involving Ms. Brosgart that would require disclosure under Item 404(a) of Regulation S-K"
current report on Form 8-K regulatory
"Pursuant to the requirements of the Securities Exchange Act of 1934"
A current report on Form 8-K is a document that publicly traded companies file to promptly share important news or events that could affect their financial position or stock price, such as major business changes or legal issues. It helps investors stay informed about timely developments, allowing them to make better decisions about buying or selling shares.

FAQ

What board change did Cocrystal Pharma (COCP) announce on August 12, 2026?
Cocrystal Pharma announced that Carol L. Brosgart was appointed as a director, effective August 12, 2026. The Board of Directors made the appointment, and the company disclosed it in a current report on Form 8-K.

Does Cocrystal Pharma (COCP) report any family relationships for director Carol L. Brosgart?
Cocrystal Pharma states there are no family relationships between Carol L. Brosgart and any of the company’s directors or executive officers. This disclosure addresses potential conflicts of interest related to family ties in corporate governance.

Were there any special arrangements behind the selection of Carol L. Brosgart to COCP’s board?
The company states there are no arrangements or understandings between Carol L. Brosgart and any other persons pursuant to which she was selected as a director. This suggests her appointment was made directly by the Board without side agreements.

Who signed the COCP Form 8-K announcing Carol L. Brosgart’s appointment?
The Form 8-K was signed on behalf of Cocrystal Pharma by James Martin, the company’s Chief Financial Officer. The signature date disclosed is August 18, 2026, confirming officer-level authorization of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001412486 0001412486 2026-08-12 2026-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 12, 2026

 

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38418   35-2528215

(State or other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

19805 N. Creek Parkway

Bothell, WA

   98011
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (877) 262-7123

 

(Former name or former address, if changed since last report.): n/a

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   COCP   The Nasdaq Stock Market, LLC
(The Nasdaq Capital Market)

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d)

 

On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. Brosgart as a director of the Company, effective immediately.

 

There are no arrangements or understandings between Ms. Brosgart and any other persons, pursuant to which she was selected as a director, no family relationships among any of the Company’s directors or executive officers and Ms. Brosgart, and there are no related party transactions involving Ms. Brosgart that would require disclosure under Item 404(a) of Regulation S-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Description
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cocrystal Pharma, Inc.
     
Date: August 18, 2026 By: /s/ James Martin
  Name: James Martin
  Title: Chief Financial Officer

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents